Phibro Animal Health Corporation
NASDAQ:PAHCDrug Manufacturers - Specialty & Generic
+$0.38 today
- Market cap
- $1.44B
- Beta
- 0.46
- P/E (TTM)
- 13.3
- EPS (TTM)
- $2.35
- Dividend yield
- 1.54%
Volume 0.11M
Average 0.37M
PAHC Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Phibro Animal Health CorporationNASDAQ: PAHC
Net Margin · Q3 FY2026 · quarter ended Mar 2026
Net margin holds steady near 6.3%
Net margin was 6.3% in Q3 FY2026, up 0.3 pp from a year earlier. On a trailing-twelve-month basis it was 6.3%, up 3.7 pp year over year. Over 3 fiscal years it narrowed by 1.5 pp.
Context
- Net margin widened in 1 of the last 3 fiscal years.
What to watch
Whether net margin reaches the consensus estimate from 4 analysts of 8.4% for the fiscal year ending Jun 2026, up from 3.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 6.3%-1.1 pp QoQ
- Last fiscal yearJun 2025
- 3.7%+3.5 pp YoY
- LTMMar 2026
- 6.3%+3.7 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +0.3 pp | +3.1 pp | +2.9 pp |
| 1 year | +3.5 pp | +4.7 pp | +1.2 pp |
| 3 years | -1.5 pp | +6.0 pp | +7.5 pp |
| 5 years | +7.8 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 3.7%
- Year-over-year change
- +3.5pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 3.7% | +3.5pp |
| FY2024 | 2024-06-30 | 0.2% | -3.1pp |
| FY2023 | 2023-06-30 | 3.3% | -1.9pp |
| FY2022 | 2022-06-30 | 5.2% | -1.3pp |
| FY2021 | 2021-06-30 | 6.5% | — |
Net Margin vs competitors
How PAHC compares with its peers on the latest reported figures
- PAHC's LTM Mar 2026 net margin of 6.3% is the 2nd highest of the 6 companies compared; the peer median is -2.9%.
- Its year-over-year change of +3.7 pp is the 2nd highest of 6, against a peer median of -3.6 pp.
- Over three fiscal years its change of -1.5 pp compares with a peer median of +1.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 27.5% | -0.3 pp | +2.1 pp | |
| LTM Mar 2026 | 6.3% | +3.7 pp | -1.5 pp | |
| LTM Jun 2026 | 4.8% | -21.0 pp | +3.6 pp | |
| LTM Sep 2026 | -2.9% | -3.6 pp | -3.2 pp | |
| LTM Aug 2026 | -6.3% | +111.3 pp | +1.9 pp | |
| FY2025 | -60.0% | -66.0 pp | -77.9 pp | |
| Peer median (excluding PAHC) | -2.9% | -3.6 pp | +1.9 pp | |
Competitors are the stored peer set for PAHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 833.35M | 942.26M | 977.89M | 1.02B | 1.3B |
| Cost of Revenue | 561.97M | 656.86M | 679.65M | 704.59M | 896.27M |
| Gross Profit | 271.38M | 285.4M | 298.24M | 313.09M | 399.94M |
| Gross Margin | 32.6% | 30.3% | 30.5% | 30.8% | 30.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 196.51M | 206.41M | 226.39M | 259.78M | 289.48M |
| Operating Expenses | 196.51M | 206.41M | 226.39M | 259.78M | 289.48M |
| Depreciation & Amortization | 31.88M | 32.71M | 34.01M | 36.18M | 45.61M |
| EBITDA | 110.21M | 117.13M | 106.03M | 69.06M | 146.85M |
| EBITDA Margin | 13.2% | 12.4% | 10.8% | 6.8% | 11.3% |
| Operating Income | 74.87M | 78.99M | 71.85M | 53.32M | 110.47M |
| Operating Margin | 9.0% | 8.4% | 7.3% | 5.2% | 8.5% |
| Interest Income | 838K | 816K | 3.36M | 4.47M | 2.62M |
| Interest Expense | 10.4M | 12.1M | 17.95M | 21.97M | 33.25M |
| Other Income / Expenses | (8.4M) | (6.66M) | (17.78M) | (42.4M) | (42.47M) |
| Income Before Tax | 66.47M | 72.33M | 54.07M | 10.92M | 67.99M |
| Pre-Tax Margin | 8.0% | 7.7% | 5.5% | 1.1% | 5.2% |
| Income Tax Expense | 12.08M | 23.15M | 21.47M | 8.5M | 19.73M |
| Net Income | 54.39M | 49.18M | 32.61M | 2.42M | 48.26M |
| Net Margin | 6.5% | 5.2% | 3.3% | 0.2% | 3.7% |
| EPS (Basic) | 1.34 | 1.21 | 0.81 | 0.06 | 1.19 |
| EPS (Diluted) | 1.34 | 1.21 | 0.81 | 0.06 | 1.19 |
| Weighted Avg Shares | 40.5M | 40.5M | 40.5M | 40.5M | 40.5M |
| Weighted Avg Shares (Diluted) | 40.5M | 40.5M | 40.5M | 40.52M | 40.7M |
Phibro Animal Health Corporation
NASDAQ:PAHC
Intrinsic Alpha fair value
Locked
Current Price
$35.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.